pCR predicted better EFS for patients with HER2+ breast cancer (HR 0.67, 95 per cent c.i. 0.60 to 0.74, P < 0.001, I2 = 0 per cent; 41 studies) (Fig. 2 and Fig. S1). Here, ERBB2 is linked to breast cancer.